Cerus raised 2026 product revenue guidance to $229 million-$231 million, up 11%-12% year over year.
The company increased its 2026 IFC sales outlook to $23 million-$25 million, up 40%-50% year over year.
Cerus anticipates a regulatory decision on the INT200 device in early 2027.
Result drivers
IFC demand — Q2 demand for INTERCEPT Fibrinogen Complex rose about 20% year over year, with U.S. IFC sales up, which the CEO cited as a key growth driver.
Broad-based product growth — Product revenue growth was driven by increases across all product categories and regions.
Gross margin pressure — Gross margin declined due to a weaker U.S. dollar versus the euro and higher product costs from inflation.
Quarterly results
Cerus said its U.S. blood safety technology firm's Q2 product revenue rose 10% year over year, while total revenue increased 5%.
Q2 adjusted EBITDA was positive but missed analyst expectations.
CERS•
